Annual General Meeting
London, UK, 9 May 2006
Lombard Medical Technologies PLC today held its Annual General Meeting in London at which the resolutions set out in the Notice of the Annual General Meeting sent to shareholders with the 2005 Annual Report were carried by the requisite majority.
The company also confirmed today that the first implant occurred in April in the US clinical trial of the Aorfix™ endovascular stent graft in the treatment of abdominal aortic aneurysms. The procedure was a success and the patient is well.
Enquiries:
Lombard Medical Technologies PLC Tel: 01235 750 800
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer
Financial Dynamics Tel: 020 7831 3113
David Yates / John Gilbert
Notes to editors
Lombard Medical is a medical devices company developing stent grafts and other medical products for use in the treatment of vascular disease. The Company’s lead product, Aorfix™, is a stent graft for the treatment of aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Abdominal and thoracic aortic aneurysms are the 13th largest cause of death in the US and the market is estimated to be worth approximately US$2 billion by 2010. Aorfix™ is currently being commercialised in the EU, with US clinical trials having recently commenced. The Company has a strategic collaboration with one of the world’s leading medical devices companies, Boston Scientific.
Lombard Medical has recently successfully completed its initial public offering on AIM and was admitted to listing in December 2005, raising £23.9 million, net of expenses. The Company, based in Oxfordshire & Yorkshire, currently employs 60 people.
Further background on the Company can be found at www.lombardmedical.com